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Abstract
Introduction: The number and quality of existing patient 
registries are not known in Portugal. In order to improve the 
knowledge regarding this issue, an interactive tool (RegisPt) 
was developed to identify and characterize all available pa-
tient registries in our country. This article aims to describe 
the RegisPt design, data model, and due functionalities. 
Methods: RegisPt was developed in Microsoft Office Access 
2010 and all variables definitions were done according to 
standardized international classifications. A review of the 
available literature and web resources was performed in or-
der to identify all relevant patient registries. Results: The 
RegisPt platform is divided into 5 core modules containing 
comprehensive information from each patient registry (gen-
eral data, registry design, characterization, effectiveness, 
and publications). Effectiveness is of utmost importance for 
health technology assessment and is divided into 2 sections: 
the exposure (health care service, pharmaceutical drugs, and 
medical devices) and the outcomes (safety, clinical, and eco-
nomic). The RegisPt platform allows adding and editing reg-
istries as well as consulting all available registries in an inter-
active and user-friendly way, using a preferred query (e.g., 
registry name, institution, and therapeutic area). About 50 
patient registries were identified and characterized in Portu-
gal in accordance with the patient registry definition of the 
International Society for Pharmacoeconomics and Out-
comes Research (ISPOR). Discussion: The RegisPt is a first 
step to better understand and use the available resources for 
health research in Portugal. RegisPt can promote collabora-
tion between researchers and registry owners and encour-
age the efficient use of resources and may improve the ac-
cess to registries. This project may also be useful to identify 
therapeutic areas still lacking patient registries and to opti-
mize existing ones in the country, by comparing registry de-
sign, quality, and functional strategies. In the future, this 
valuable platform may be particularly relevant for research-
ers and authorities aiming to carry out health technology 
assessment. © 2017 The Author(s). Published by S. Karger AG, Basel
on behalf of NOVA National School of Public Health
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Resumo
Introdução: O número e a qualidade dos registos de 
doentes existentes em Portugal não são inteiramente 
conhecidos. Com o objetivo de melhorar o conhecimento 
nesta área, foi desenvolvida uma ferramenta interativa 
(RegisPt) para identificar e caracterizar todos os registos 
de doentes disponíveis no nosso país. Este artigo de-
screve a estrutura e o desenho do RegisPt, o modelo de 
dados recolhidos e as respetivas funcionalidades. Méto-
dos: O RegisPt foi desenvolvido em Microsoft Office Ac-
cess 2010 e todas as definições de variáveis basearam-se 
em classificações internacionais. Foi realizada uma re-
visão de literatura para identificar e caracterizar todos os 
registos de doentes relevantes. Resultados: A plataforma 
RegisPt está dividida em cinco módulos principais que 
contêm informações abrangentes de cada registo de 
doentes (Dados Gerais, Desenho do Registo, Caracteriza-
ção, Efetividade e Publicações). Em particular, o módulo 
de Efetividade é de extrema importância para a Avaliação 
de Tecnologias em Saúde e está dividido em duas seções 
principais: Exposição (Serviço de Saúde, Medicamentos e 
Dispositivos Médicos) e Resultados (Segurança, Out-
comes Clínicos e Económicos). A plataforma RegisPt per-
mite adicionar e editar registos, bem como consultar to-
dos os registos disponíveis de forma simples e interativa, 
através de pesquisas específicas (por exemplo, nome do 
registo, instituição e área terapêutica). Cerca de 50 regis-
tos de doentes foram identificados e caracterizados de 
acordo com a definição adotada pela International Soci-
ety for Pharmacoeconomics and Outcomes Research 
(ISPOR). Discussão: O RegisPt é um primeiro passo para 
melhor entender e utilizar os recursos disponíveis para in-
vestigação em saúde realizada em Portugal. O RegisPt 
poderá promover a colaboração entre investigadores e 
responsáveis de registos, bem como incentivar a utiliza-
ção eficiente de recursos e melhorar o acesso aos registos 
já existentes. Este projeto poderá ainda ser útil para iden-
tificar áreas terapêuticas com lacuna de registos de doen-
tes e para otimizar aqueles já existentes. No futuro, esta 
plataforma poderá ser particularmente relevante para in-
vestigadores e Autoridades para a eficiente implementa-
ção da Avaliação de Tecnologias em Saúde em Portugal.
© 2017 The Author(s). Published by S. Karger AG, Basel
on behalf of NOVA National School of Public Health
Introduction
The Portuguese National Health Service (NHS) is cur-
rently under high pressure to become more efficient, by 
treating better with fewer resources. This reality influenc-
es policy makers, researchers, and healthcare profession-
als. It affects the whole decision-making process in the 
healthcare area and all due allocation of needed resources. 
Good quality knowledge about disease patterns and po-
tential interventions, such as healthcare technologies, is 
needed in order to help deciders making reasoned and 
sustainable decisions about the future of the NHS. Al-
though clinical guidelines and support for decision-mak-
ing mainly comes from clinical trials and evidence from 
abroad, the need for knowing our own reality, namely the 
epidemiologic patterns, and the effectiveness of available 
policies and interventions is increasing. Moreover, a con-
sensus exists on the general need for greater availability 
of real world data (RWD) [1].
Registries represent one of the main sources of RWD. 
The use of registries was initiated in the 1930s in the UK 
and USA as a means to systematically collect data on can-
cer patients [2]. In 1949, the term “registry” was defined 
as a “system of recording frequently used in the general 
field of public health which serves as a device for the ad-
ministration of programs concerned with the long-term 
care, follow-up or observation of individual cases” [3]. 
Over the last decades, several definitions have been pro-
posed by the World Health Organization and US Nation-
al Committee on Vital and Health Statistics among other 
entities [4]. Despite variations in definition, it is clear that 
a registry involves a long-term, systematic, and organized 
process of collecting data, which is driven by specific, pre-
defined aims [1]. Nowadays, the US Agency for Health-
care Research and Quality (AHRQ) defines “patient reg-
istry” as “an organized system that uses observational 
study methods to collect uniform data (clinical and other) 
to evaluate specified outcomes for a population defined 
by a particular disease, condition, or exposure, and that 
serves one or more predetermined scientific, clinical, or 
policy purposes” [4]. In line with this definition, the In-
ternational Society for Pharmacoeconomics and Out-
comes Research (ISPOR) also has its own definition of 
“patient registry” [5].
As a direct response to the objective set in Article 14(2)
b of the healthcare Directive 2011/24/EU, the Member 
States and the European Commission created the “PAR-
ENT Joint Action”, cross-border PAtient REgistries 
iNiTiative to improve secondary use of data from patient 
registries in a cross-border setting for both public health 
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and research needs. To achieve one of their objectives, the 
PARENT launched an online tool “Registry of Registries 
(RoR)” available at http://www.parent-ror.eu with the 
aim of mapping patient registries in the European Union 
with the purpose of supporting search and identification 
of available data sources, and exchanging information 
about national best practices and lessons learnt on patient 
registries [1].
Other initiatives are also known, including Registry of 
Patient Registries (RoPR) in the USA. In addition, there 
are also several other examples such as DoCDat – Direc-
tory of clinical databases in the UK [6], Monash Clinical 
Registries in Australia [7], Health Information and Qual-
ity Authority (HIQA) in Ireland, and Sweden Quality 
Registries in Sweden. Although these international orga-
nizations contain comprehensive lists of patient regis-
tries, the level of registry characterization varies signifi-
cantly across the several lists of patient registries.
In Portugal, despite the growing need of RWD, we still 
do not know exactly the current situation in our country 
when it comes to patient registries, namely regarding the 
number, the quality, and the clinical areas already cov-
ered. The existence of a searchable public website (or da-
tabase) designed specifically to provide information 
about patient registries in Portugal would result in a sig-
nificant resource for improving the efficiency for our 
NHS. Essentially, such a database would prevent unnec-
essary duplication of registries, reduce redundancies, 
identify gaps in research and epidemiologic data, enable 
researchers to understand the quality of data within reg-
istries, support research collaborations, encourage the ef-
ficient use of resources, and improve quality and trans-
parency in observational research. Thus, in an attempt to 
improve the knowledge of existing patient registries in 
Portugal, we developed an interactive tool (RegisPt) that 
identifies and characterizes all available patient registries 
in Portugal. Ultimately, a registry of registries may be a 
major contribution to boost evidence-based decisions in 
our healthcare sector. This article aims to describe the 
RegisPt design, data model, and due functionalities. 
Methods
The RegisPt was developed in several phases.
Phase I
Identification of variables to be included in RegisPt using 2 
main guiding documents: “Registries for Evaluating Patient Out-
comes: A User’s Guide” [4] and “ISPOR Taxonomy of Patient Reg-
istries: Classification, Characteristics and Terms” [5].
Phase II
Five core modules were built in order to group all the previ-
ously selected variables: 
General Data
This module includes the description of the registry, relevant 
administrative information (e.g., ownership, main scientific con-
tact, website, and institutional address), registry classification (i.e., 
disease, health technology, health management/health services), 
and due clinical and therapeutic area. Additionally, this module 
describes the type of investigators (e.g., physicians, pharmacists, 
and other healthcare professionals), the type and number of sites 
involved in the registry, the number of enrolled patients, and rel-
evant milestones, such as the year when the registry started.
Registry Design
This module identifies the data sources used to collect data in 
the registry (e.g., clinician- and/or patient-reported data), the 
main purpose (e.g., effectiveness and safety monitoring), and the 
patients’ eligibility criteria. This module also contains information 
about the frequency and description of the assessments and the 
type of outcomes that are collected in the registry and identifies the 
potential research outputs that may be achieved using its data (e.g., 
persistence studies, burden of illness, and cost-effectiveness analy-
sis). 
Characterization
This module is divided into 6 sections. The first section aims to 
list the socio-demographic variables collected by the registry. The 
following sections aggregate variables related with quality of life 
and functional measures, occupational data, lifestyle, healthcare 
access, and clinical data. All variables may be characterized in ac-
cordance with the moment of data collection (i.e., baseline and 
follow-up).
Effectiveness
This module is divided into 2 sections. The exposure section 
aims to characterize the variables related with the healthcare inter-
vention (i.e., healthcare service, pharmaceutical drugs, and medi-
cal devices). Pharmaceutical drugs and medical devices may be 
selected from predefined lists imported from INFARMED’s data-
bases (https://www.infarmed.pt/infomed/inicio.php and https://
app.infarmed.pt/dec_hosp/pages/cdmpublic.aspx), which contain 
relevant information already filled in line with standardized clas-
sifications (e.g., drug substance, brand name, dosage form, 
strength, marketing authorization holder, medical device code, 
and manufacturer). The outcomes section aims to characterize the 
variables related with the potential outcomes that might be ana-
lyzed following an intervention collected in a given registry, en-
compassing safety, effectiveness (e.g., surrogate markers and pre-
specified hard clinical endpoints), and economic outcomes (e.g., 
healthcare resource utilization and productivity losses). 
Publications
This module aims to list all scientific publications related with 
information retrieved from the registry. 
Phase III
Development and testing of the RegisPt IT platform using Mi-
crosoft Office Access 2010. 
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Phase IV
Identification and characterization of all available Portuguese 
patient registries. A review of available literature and web resourc-
es was performed in order to identify and characterize all patient 
registries taking into consideration the variables selected in 
RegisPt. The adopted criteria used for the inclusion of registries in 
the RegisPt was the patient registry definition of ISPOR, which 
defines a “patient registry” as “a prospective observational study of 
patients, sharing some common characteristics over time, which 
collects ongoing and supporting data on well-defined outcomes of 
interest for analysis and reporting” [5]. There were no further cri-
teria applied in the selection of patient registries.
Phase V
In order to gather sustainable support from other relevant enti-
ties, important partnerships were created with the following insti-
tutions: Fundação Calouste Gulbenkian, Escola Nacional de Saúde 
Pública, Instituto Nacional Ricardo Jorge and Capítulo Português 
do ISPOR. A Scientific Committee was established with represen-
tatives of each partner, which will be responsible for the overall 
strategy, oversight, and governance of the RegisPt.
Phase VI
Systematic contact, validation, and further data input by the 
respective registries’ owners in order to complete and validate the 
RegisPt database (this phase is still ongoing).
Results
Over 50 patient registries were identified in Portugal 
according with the above-mentioned definition of ISPOR. 
Furthermore, during the development and early imple-
mentation of RegisPt, about 60 other epidemiological da-
tabases were found, which fell outside this definition. 
These databases were also listed and characterized in their 
own repository, labeled “other databases” defined as 
“other records/databases not fulfilling the patient registry 
definition of ISPOR.”
The RegisPt platform allows the addition of new reg-
istries and the edition of any already listed, without any 
access to specific patient’s data. It also allows an interac-
tive and user-friendly search, using a preferred query 
(e.g., registry name, institution, and therapeutic area). 
Navigation through each of the selected registries is sim-
ple and straightforward. Editing of the RegisPt platform 
is restricted to register users with due privileges previ-
ously granted by the RegisPt Scientific Committee. The 
system is prepared to set different levels of user privileges 
(from read-only to administrator rights). All addition or 
editing actions done in the RegisPt platform are subject 
to prior approval and are automatically notified to the 
Scientific Committee through an e-mail with the details 
of performed additions/edits. This Committee is respon-
sible for approving or declining any proposed addition/
editing done in the system.
RegisPt has a track record system in place allowing the 
Scientific Committee and the system’s administrators to 
have access to the database administration module, where 
they can view all past editing performed in the RegisPt 
and all decisions that were performed since the beginning 
of the RegisPt (see online suppl. Fig.  1; see www. 
karger.com/doi/10.1159/000479778 for all online suppl. 
material).
Discussion
The number of existing patient registries and their area 
of intervention are not known in Portugal. RegisPt con-
sist in an interactive platform that aims to identify and 
characterize all available patient registries in the country. 
This initiative is an ongoing project and until now, we 
have identified and characterized about 50 patient regis-
tries and 60 other databases. 
RegisPt may promote collaboration between research-
ers and registry owners, encourage the efficient use of re-
sources, reduce redundancy, improve the transparency in 
registry-based research, and facilitate the access to infor-
mation about registries as well as the overall quality of 
clinical records in Portugal. This project may also be use-
ful to identify therapeutic areas still lacking patient regis-
tries, to discourage initiatives aiming to collect evidence 
already covered by other registries, and to optimize exist-
ing ones, while making a critical contribution in making 
better decisions in public health.
The importance of projects like RegisPt and others at 
the European level have already been recognized by re-
searchers, policy makers, and other stakeholders, namely 
to support health technology assessment (HTA) [1, 8]. 
HTA and particularly health economic evaluations can be 
useful tools to help prioritizing new interventions, be-
cause they illustrate the costs and health outcomes associ-
ated with the different interventions [9]. In a time of eco-
nomic constraints, not all new interventions that are ef-
fective may be introduced and/or maintained in the 
healthcare systems. Therefore, reliable tools that help this 
sort of analytical methods and decisions are of paramount 
importance.
Traditionally, the HTA depends on data generated by 
randomized controlled trials and literature reviews on 
the subject. Although they are considered as a “gold stan-
dard” in clinical efficacy, these studies have some limita-
tions. Typically, they are conducted during a short peri-
Laires/BarrosPort J Public Health 2017;35:126–131130
DOI: 10.1159/000479778
od of time, in a well-defined population with the aim of 
establishing clinical efficacy and safety, with specific in-
clusion and exclusion criteria, and under almost “labora-
tory-like” conditions [10]. Due to these methodological 
characteristics, their results cannot be extrapolated to 
uncontrolled environments as the real clinical practice 
[10].
In HTA, data from registries may serve as a source of 
real-world evidence about the “effectiveness” of treat-
ments. Hence, it is clear that data from patient registries 
can supplement the data from randomized controlled 
trials, because it allows having a more realistic view of the 
true impact of a given treatment in the population (i.e., 
real-world treatment effect) [10]. The use of patient reg-
istries has several potentialities, such as to observe the 
clinical course of a disease, to illustrate practice patterns 
and variations of them, to determine clinical effective-
ness and/or cost-effectiveness, to assess safety or harm, 
to explore humanistic outcomes, including health-relat-
ed quality of life and other patient-reported outcomes, 
and to track economic data, namely resource utilization 
[8].
Portugal is no exception to the global resources scar-
city scenario and the reinforced need to take into account 
the sustainability of the NHS. This situation has led to the 
new HTA system implemented in our country, called 
“Sistema Nacional de Avaliação de Tecnologias de Saúde” 
(SiNATS), which introduced substantial changes in the 
previous model of technology assessment in health. The 
SiNATS main objectives are to maximize health gains and 
the quality of life of the citizens, to contribute to sustain-
ability of the NHS, to guarantee efficient use of public 
resources in health, to monitor the use and technologies, 
to reduce waste and inefficiencies, to promote and reward 
relevant innovation development, and to promote equi-
table access to technologies [11].
Among several important changes to the old model, 
this new system introduces a reassessment of technolo-
gies (ex post evaluation), based on effectiveness monitor-
ing on patient registries, showing a paradigm change in 
the HTA setting in Portugal. Within this new system, an 
information system for HTA (SiATS – Sistema de Infor-
mação para a Avaliação das Tecnologias de Saúde) was 
initiated that aims to monitor all data sources and existing 
patient registries that may support the assessments of new 
products in the future. SiATS will prioritize the following 
patient registries at a national level: (1) oncology (nation-
al oncologic registry), (2) HIV/AIDS, (3) rare diseases/
orphan products, (4) medical devices (cardiology), and 
(5) hepatitis C (already in use) [11].
In Portugal, the current situation about existing pa-
tient registries is unknown. Within the framework of this 
new national HTA system and taking into account the 
need of patient registries as data source for reassessment 
of new technologies in the market, the RegisPt can be 
viewed as an useful tool for the activity of SiNATS and be 
used as a starting point for the much needed discussion 
regarding the availability of data sources for the execution 
of their aims. Arguably, RegisPt might be a valuable re-
source for SiNATS. Overall, by increasing the public 
knowledge of patient registries, RegisPt may contribute 
to accelerating the most needed evidence-based decisions 
in our healthcare sector.
Future Perspectives
Despite the potential benefits of patient registries, 
there are some limitations that need to be highlighted, 
which in turn influence its utilization as a primary data 
source for reassessment of technologies, clinical research, 
clinical audit, or planning and management of clinical 
services. The use of registries is not only conditioned by 
the lack of knowledge about their existence/availability 
and by the coverage they have, but also by the quality of 
data included in the registry. To our knowledge, there are 
no established guidelines at the international level setting 
criteria and quality measures of patient registries. Never-
theless, some quality assessment checklists have already 
been developed, for instance in the UK [6], by other ini-
tiatives similar to RegisPt based on the approach used to 
develop CONSORT [12], the checklist assessing the qual-
ity of randomized trials. Due to the need of high-quality 
registries, governmental agencies such as the Agency for 
Healthcare Research and Quality [4] or international so-
cieties such as ISPOR [5] among others have prepared 
and published dossiers to guide healthcare organizations 
towards planning and implementation of new registries. 
On this regard, the RegisPt Scientific Committee will try 
to develop a quality assessment checklist based on the 
available literature and in the experience of similar proj-
ects. This checklist might then be applied to all registries 
included in our database. Finally, RegisPt will be soon ac-
cessible to the scientific community and the general pub-
lic through a public website that will allow any user to 
consult all patient registries identified in Portugal and to 
view all variables collected by each registry. This may 
highlight the therapeutic areas still needing to be covered 
by a patient registry and might also help to raise the cur-
rent quality standards for the ongoing registries, not only 
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in terms of the quality of data being collected and regis-
tered, but also regarding the interconnectivity within the 
established registries and with other databases, such as 
the hospital and death records, which is undoubtedly an 
area to improve in our country.
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